Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) and ZyVersa Therapeutics (NASDAQ:ZVSA – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
This table compares Arrowhead Pharmaceuticals and ZyVersa Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Arrowhead Pharmaceuticals and ZyVersa Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Arrowhead Pharmaceuticals||$256.21 million||10.90||-$176.06 million||($1.71)||-15.24|
|ZyVersa Therapeutics||N/A||N/A||-$14.12 million||N/A||N/A|
Risk & Volatility
Arrowhead Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
Institutional & Insider Ownership
66.0% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 36.7% of ZyVersa Therapeutics shares are held by institutional investors. 5.0% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings and price targets for Arrowhead Pharmaceuticals and ZyVersa Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Arrowhead Pharmaceuticals currently has a consensus target price of $54.53, suggesting a potential upside of 109.26%. ZyVersa Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 3,206.88%. Given ZyVersa Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe ZyVersa Therapeutics is more favorable than Arrowhead Pharmaceuticals.
ZyVersa Therapeutics beats Arrowhead Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.